These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15655900)

  • 1. Biological pathophysiology of mood disorders special reference to the neurotransmitter receptors.
    Suhara T; Fujimura Y
    Seishin Shinkeigaku Zasshi; 2004; 106(8):1032-6. PubMed ID: 15655900
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pathophysiology of mood disorders and the therapy].
    Suhara T; Ichimiya T
    Seishin Shinkeigaku Zasshi; 2002; 104(6):464-71. PubMed ID: 12373801
    [No Abstract]   [Full Text] [Related]  

  • 3. [Correction of affective disorders in patients with alcohol dependence].
    Litvintsev SV; Reznik AM; Arbuzov AL; Kutushev OT; Martyniuk IuL; Khurbatova IG
    Voen Med Zh; 2002 Jul; 323(7):42-5. PubMed ID: 12192987
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuropharmacology of paroxetine.
    Nemeroff CB; Owens MJ
    Psychopharmacol Bull; 2003; 37 Suppl 1():8-18. PubMed ID: 14566196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Overview of mood disorders--recent advances in the field of diagnoses, pathophysiology and treatment].
    Higuchi T
    Ryoikibetsu Shokogun Shirizu; 2003; (38):227-31. PubMed ID: 12876971
    [No Abstract]   [Full Text] [Related]  

  • 6. Depression: more than just serotonin.
    Secko D
    CMAJ; 2005 Jun; 172(12):1551. PubMed ID: 15939910
    [No Abstract]   [Full Text] [Related]  

  • 7. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
    Celada P; Puig M; Amargós-Bosch M; Adell A; Artigas F
    J Psychiatry Neurosci; 2004 Jul; 29(4):252-65. PubMed ID: 15309042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of S-citalopram and paroxetine discriminates between species.
    Elfving B; Wiborg O
    Synapse; 2005 Mar; 55(4):280-2. PubMed ID: 15668984
    [No Abstract]   [Full Text] [Related]  

  • 9. [Trazodone--its multifunctional mechanism of action and clinical use].
    Frecska E
    Neuropsychopharmacol Hung; 2010 Dec; 12(4):477-82. PubMed ID: 21220793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trazodone increases extracellular serotonin levels in the frontal cortex of rats.
    Pazzagli M; Giovannini MG; Pepeu G
    Eur J Pharmacol; 1999 Nov; 383(3):249-57. PubMed ID: 10594316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
    Sanchez C; Reines EH; Montgomery SA
    Int Clin Psychopharmacol; 2014 Jul; 29(4):185-96. PubMed ID: 24424469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter.
    Neumeister A; Young T; Stastny J
    Psychopharmacology (Berl); 2004 Aug; 174(4):512-24. PubMed ID: 15249991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paxil (paroxetine) lifts depression, lowers associated anxiety symptoms.
    Adv Nurse Pract; 1997 Oct; 5(10):71. PubMed ID: 9459990
    [No Abstract]   [Full Text] [Related]  

  • 14. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors.
    Kugaya A; Sanacora G; Staley JK; Malison RT; Bozkurt A; Khan S; Anand A; Van Dyck CH; Baldwin RM; Seibyl JP; Charney D; Innis RB
    Biol Psychiatry; 2004 Oct; 56(7):497-502. PubMed ID: 15450785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serotonin neurotrasmission and treatment options for depression].
    Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):174-177. PubMed ID: 29265105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.
    Hirano K; Kimura R; Sugimoto Y; Yamada J; Uchida S; Kato Y; Hashimoto H; Yamada S
    Br J Pharmacol; 2005 Mar; 144(5):695-702. PubMed ID: 15678084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Paroxetine (paxil): use in clinical practice].
    Litvintsev SV; Reznik AM; Arbuzov AL; Mironychev GN
    Voen Med Zh; 2002 Jan; 323(1):35-9. PubMed ID: 11881199
    [No Abstract]   [Full Text] [Related]  

  • 18. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.
    Dawson LA; Watson JM
    CNS Neurosci Ther; 2009; 15(2):107-17. PubMed ID: 19499624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.
    Béïque JC; Lavoie N; de Montigny C; Debonnel G
    Eur J Pharmacol; 1998 May; 349(1):129-32. PubMed ID: 9669506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.